HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on KalVista Pharma (NASDAQ:KALV) and maintained a $16 price target.

September 08, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
KalVista Pharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $16.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $16 also indicates the firm's confidence in the stock's potential. This could lead to increased investor confidence and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100